Health technology assessment (Winchester, England) , 13 (27), iii163
Abdominal obesity In a 12-month clinical trial published in 2010, which involved 404 HIV-infected patients with excess abdominal fat, the group that received 2mg of tesamorelin per day saw an 18% decrease in visceral fat compared to placebo.9 There are two things to note in order to appreciate the full scope of these findings: Visceral fat (i.e., fat accumulation around the abdominal organs) is famously stubborn and cant be burned selectively through exercise
Which Peptide Is Best for Your Goals
injection, with some vendors offering blends in capsules for convenience, while others focus on research-grade injectables
This content is for educational purposes only
The lack of data in this area indicates that further experimentation is warranted with both sermorelin and a sermorelin-ipamorelin blend